Publications by authors named "Z Kuzmina"
Article Synopsis
- The clinical study aimed to evaluate the effect of Crizal Prevencia, a non-invasive selective blue-filtering lens, on benign essential blepharospasm (BEB) treatment.
- Twenty-four patients participated in a randomized, double-blind, cross-over study, measuring blink frequency under various conditions before and after wearing either the blue-filtering lens or a placebo.
- While the lens showed a reduction in blink frequency in some specific tests compared to the placebo, it did not show significant improvement compared to baseline, indicating it may be a beneficial, non-invasive option alongside existing treatments like botulinum neurotoxin therapy.
Thyroid disorders are well-studied after allogeneic haematopoietic stem cell transplantation (HSCT) following total body irradiation (TBI)-based conditioning, occurring in 15-30% of paediatric survivors. The toxic effect of TBI is known but data on the role of immunological dysregulation (ID) and chronic graft-versus-host-disease (cGvHD) are scarce. We studied functional and structural thyroid disorders in 97 paediatric ALL patients after TBI-based HSCT, assessing their correlation with patient/transplant characteristics including cGvHD, prolonged immunosuppression and ID.
View Article and Find Full Text PDFChronic graft-versus-host disease (cGvHD) following haematopoietic stem cell transplantation (HSCT) shares many similarities with autoimmune disorders, being associated with the presence of autoantibodies. However, data on the implication of autoantibodies in paediatric HSCT recipients are scarce. In this single-centre study of paediatric patients with acute lymphoblastic leukaemia (ALL) surviving longer than 3 months, our objectives were to evaluate autoantibody expression and investigate the correlation with cGvHD and immune reconstitution using serially monitored parameters.
View Article and Find Full Text PDFSteroid-refractory chronic graft-versus-host disease (cGVHD) is a therapeutic challenge. Sclerotic skin manifestations are especially difficult to treat. We conducted a randomized phase 2 clinical trial (#NCT01688466) to determine the safety, efficacy, and preferred dose of pomalidomide in persons with moderate to severe cGVHD unresponsive to corticosteroids and/or subsequent lines of therapy.
View Article and Find Full Text PDF